These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23426530)

  • 1. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
    Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycoside volume of distribution and illness severity in critically ill septic patients.
    Marik PE
    Anaesth Intensive Care; 1993 Apr; 21(2):172-3. PubMed ID: 8517507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
    Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
    Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
    Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
    Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin population pharmacokinetics among paediatric burn patients.
    Sherwin CM; Wead S; Stockmann C; Healy D; Spigarelli MG; Neely A; Kagan R
    Burns; 2014 Mar; 40(2):311-8. PubMed ID: 23876785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
    Roger C; Nucci B; Louart B; Friggeri A; Knani H; Evrard A; Lavigne JP; Allaouchiche B; Lefrant JY; Roberts JA; Muller L
    J Antimicrob Chemother; 2016 Jan; 71(1):208-12. PubMed ID: 26429564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of amikacin in preterm and term infants.
    Siddiqi A; Khan DA; Khan FA; Razzaq A
    Singapore Med J; 2009 May; 50(5):486-9. PubMed ID: 19495517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
    De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
    Marsot A; Guilhaumou R; Riff C; Blin O
    Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.
    Zaske DE; Cipolle RJ; Rotschafer JC; Kohls PR; Strate RG
    Ther Drug Monit; 1991 Nov; 13(6):502-6. PubMed ID: 1771647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.